“…In empirical analyses of drug approval times by the FDA, for example, Dranove and Meltzer (1994) and Olson (1997Olson ( , 2000 both found that the speed of drugs through the regulatory process is significantly affected by the ''importance'' of the drug. Other studies, not on regulatory processing times but on final regulatory outcomes, by Magat et al (1986), Bartel and Thomas (1987), Cropper et al (1992), Olson (1995Olson ( , 1997Olson ( , 2000, Mixon (1994), Crone and Tschirhart (1998), and Ando (2001), confirm that case-specific variables are generally significant in affecting regulatory decisions. This analysis includes a host of case-specific variables, including size of the dam being relicensed, environmental quality of the river upon which the dam is being relicensed, and value of the electricity generated by the dam in order to determine these alternative workload factors which of may affect regulatory delay.…”